Navigating systemic therapy for metastatic castration-naïve prostate cancer

被引：0
|
作者：
E. M. Kwan
I. A. Thangasamy
J. Teh
O. Alghazo
N. J. Sathianathen
N. Lawrentschuk
A. A. Azad
机构：
[1] Monash University,Department of Medicine, School of Clinical Sciences
[2] Monash Health,Department of Medical Oncology
[3] University of Melbourne,Division of Cancer Surgery, Peter MacCallum Cancer Centre
[4] University of Queensland,Faculty of Medicine
[5] University of Melbourne,Department of Surgery
[6] Austin Hospital,Department of Medical Oncology
[7] Peter MacCallum Cancer Centre,Sir Peter MacCallum Department of Oncology
[8] University of Melbourne,undefined
来源：
World Journal of Urology | 2021年 / 39卷
关键词：
Metastatic prostate cancer; Castration-naïve; Hormone-sensitive; Androgen receptor pathway inhibitors; Docetaxel; Abiraterone; Enzalutamide; Apalutamide;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：339 / 348
页数：9
相关论文
共 50 条
  • [21] Development and validation of a prognostic model for overall survival in chemotherapy-na⟨ve men with metastatic castration-resistant prostate cancer
    Armstrong, A. J.
    Lin, P.
    Higano, C. S.
    Sternberg, C. N.
    Sonpavde, G.
    Tombal, B.
    Templeton, A. J.
    Fizazi, K.
    Phung, D.
    Wong, E. K.
    Krivoshik, A.
    Beer, T. M.
    ANNALS OF ONCOLOGY, 2018, 29 (11) : 2200 - 2207
  • [22] Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review
    Hatano, Koji
    Nonomura, Norio
    WORLD JOURNAL OF MENS HEALTH, 2023, 41 (04): : 769 - 784
  • [23] Optimal Therapy Sequencing in Metastatic Castration-Resistant Prostate Cancer
    Sausan Abouharb
    Paul G. Corn
    Current Oncology Reports, 2013, 15 : 217 - 223
  • [24] Modular therapy approach in metastatic castration-refractory prostate cancer
    B. Walter
    S. Rogenhofer
    M. Vogelhuber
    A. Berand
    W. F. Wieland
    R. Andreesen
    A. Reichle
    World Journal of Urology, 2010, 28 : 745 - 750
  • [25] Optimal Therapy Sequencing in Metastatic Castration-Resistant Prostate Cancer
    Abouharb, Sausan
    Corn, Paul G.
    CURRENT ONCOLOGY REPORTS, 2013, 15 (03) : 217 - 223
  • [26] Modular therapy approach in metastatic castration-refractory prostate cancer
    Walter, B.
    Rogenhofer, S.
    Vogelhuber, M.
    Berand, A.
    Wieland, W. F.
    Andreesen, R.
    Reichle, A.
    WORLD JOURNAL OF UROLOGY, 2010, 28 (06) : 745 - 750
  • [27] Ki67 and prostate specific antigen are prognostic in metastatic hormone naïve prostate cancer
    Spyratou, Vasiliki
    Freyhult, Eva
    Bergh, Anders
    Thellenberg-Karlsson, Camilla
    Wikstrom, Pernilla
    Welen, Karin
    Josefsson, Andreas
    ACTA ONCOLOGICA, 2023, 62 (12) : 1698 - 1706
  • [28] Circulating tumor DNA (ctDNA) burden and actionable mutations in treatment-na ve metastatic castration-resistant prostate cancer (mCRPC).
    Wyatt, Alexander William
    Annala, Matti
    Parimi, Sunil
    Zulfiqar, Muhammad
    Finch, Daygen L.
    Oja, Conrad D.
    Vergidis, Joanna
    Azad, Arun
    Gleave, Martin
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [29] Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer
    Feby Mardjuadi
    Jacques Medioni
    Joseph Kerger
    Lionel D’Hondt
    Jean-Luc Canon
    Lionel Duck
    Flora Musuamba
    Stephane Oudard
    Marylene Clausse
    Anne Moxhon
    Jean-Pascal Machiels
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 293 - 303
  • [30] Population Pharmacokinetic Analysis of Abiraterone in Chemotherapy-Na⟨ve and Docetaxel-Treated Patients with Metastatic Castration-Resistant Prostate Cancer
    Stuyckens, Kim
    Saad, Fred
    Xu, Xu Steven
    Ryan, Charles J.
    Smith, Matthew R.
    Griffin, Thomas W.
    Yu, Margaret K.
    Vermeulen, An
    Nandy, Partha
    Poggesi, Italo
    CLINICAL PHARMACOKINETICS, 2014, 53 (12) : 1149 - 1160
12345